Akebia Therapeutics
Market cap $111M 277.7M shares (10-Q, Nov 2, 2026) × $0.400 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- Symbiotic loan covenant corporate updateDec 31, 2026Symbiotic loan covenant corporate update, Dec 31, 2026, routine
- AKB-9090 Ph1 toplineearly 2027AKB-9090 Ph1 topline, early 2027, major
- AKB-097 readout2027AKB-097 readout, 2027, material
- Term loan financingJan 1, 2027Term loan financing, Jan 1, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
Auryxia
ferric citratepraliciguat
ebribafusp
AKB-097 · ADX-097AKB-9090
AKB-10108
Capital (as filed)
- Cash
- $159M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- $2.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $159M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-17 UPDATE: Akebia Therapeutics (AKBA) - The Refinancing Finally Lands 🔒 Paid
- 2026-11-06 UPDATE: Akebia Therapeutics (AKBA) - More Patients, Less Revenue 🔒 Paid
- 2026-10-27 UPDATE: Akebia Therapeutics (AKBA) - VOICE Gets Its Full Hearing ★ Distilled Pro
- 2026-10-15 UPDATE: Akebia Therapeutics (AKBA) - The Commercial Chief Walks Before the Cliff 🔒 Paid
- 2026-08-06 UPDATE: Akebia Therapeutics (AKBA) - The Auryxia Curve, and a Bigger Problem in the Footnotes 🔒 Paid
- 2026-08-04 UPDATE: Akebia Therapeutics (AKBA) - The Smart Bomb Gets a Name 🔒 Paid
- 2026-06-30 UPDATE: Akebia Therapeutics (AKBA) - VOICE Stops Early 🔒 Paid
- 2026-05-08 UPDATE: Akebia Therapeutics (AKBA) - The Receipts Arrive 🔒 Paid
- 2026-03-04 Akebia (AKBA): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on Akebia Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-04 Watch Akebia (AKBA): Scientific Deep Dive for Lead and Pipeline Products Akebia is a commercial execution play with a breaching patent moat on legacy revenue; Vafseo launch traction must be demonstrated before initiating a position.
- 2026-05-08 Speculative buy speculative UPDATE: Akebia Therapeutics (AKBA) - The Receipts Arrive Vafseo's 60% QoQ patient growth and 86% refill adherence deliver the commercial receipts demanded, creating asymmetric upside ahead of the Q4 2026 VOCAL readout despite real dilution risk from accelerating cash burn.
- 2026-06-30 Buy core UPDATE: Akebia Therapeutics (AKBA) - VOICE Stops Early VOICE stopping early with win odds 1.16 (p=0.0016) on mortality-plus-hospitalization against real ESAs substantially retires the biggest scientific risk on the Vafseo franchise and improves the dilution math.
- 2026-08-04 Buy core UPDATE: Akebia Therapeutics (AKBA) - The Smart Bomb Gets a Name Ebribafusp Phase 2 initiation on schedule with encouraging Phase 1 PK data adds a pipeline leg to the thesis while VOICE's outcomes win remains the load-bearing wall; near-term risk is the Q2 Auryxia erosion print.
- 2026-08-06 Speculative buy speculative UPDATE: Akebia Therapeutics (AKBA) - The Auryxia Curve, and a Bigger Problem in the Footnotes The 2027 TDAPA cliff will force a deliberate Vafseo price reset into ESA territory while Auryxia craters 46% YoY, inverting the revenue growth assumption that underpinned the BUY; the refinancing is now the load-bearing assumption.
- 2026-10-15 Watch UPDATE: Akebia Therapeutics (AKBA) - The Commercial Chief Walks Before the Cliff CCO resignation eight weeks before the TDAPA cliff, combined with sub-$1 stock price bringing Nasdaq listing risk, removes the key commercial execution officer at the most critical transition point.
- 2026-10-27 Watch UPDATE: Akebia Therapeutics (AKBA) - VOICE Gets Its Full Hearing Full VOICE dataset at ASN strengthens the clinical story with hemoglobin-overshoot data, but none of the four conditions set for re-entry (refinancing, commercial successor, Q3 patient adds, CMS ESRD rule) have been met.
- 2026-11-06 Avoid UPDATE: Akebia Therapeutics (AKBA) - More Patients, Less Revenue Vafseo revenue fell 30% sequentially despite patient growth due to lower dose-per-patient and compliance issues, the refinancing remains undone with amortization starting in eight weeks, and the final CMS rule added uncertainty rather than crediting VOICE data.
- 2026-11-17 Watch UPDATE: Akebia Therapeutics (AKBA) - The Refinancing Finally Lands The Symbiotic refinancing removes the 2027 amortization cliff and makes the two-year runway unconditional, satisfying the first exit condition, but the second condition (post-TDAPA volume growth outpacing the price cut) remains untested.
- Long call · opened May 8, 2026 at $1.16 · closed Oct 15, 2026 (downgraded to WATCH from long) at $0.696 · -40.0% vs XBI +11.2%
- Avoid call · opened Nov 6, 2026 at $0.401 · closed Nov 17, 2026 (downgraded to WATCH from avoid) at $0.400 · -0.2% vs XBI -4.6%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Furthermore, as a result of changes in the amount of reimbursement dialysis facilities will receive for use of Vafseo when Vafseo transitions from the Transitional Drug Add-on Payment Adjustment, or TDAPA , period to the post-TDAPA period beginning in January 2027, we expect to price Vafseo within the range of the price for erythropoiesis stimulating agents, or ESAs .”
matched to Vafseo · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (31)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseAkebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
- Nov 16, 2026ReleaseAkebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million→ BD update
- Nov 16, 20268-KCurrent report: material agreement, agreement terminated, debt / obligation · EX-99.1→ BD update
- Nov 5, 2026ReleaseAkebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseAkebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateVOCAL hit its non-inferiority endpoint against ESA, completing the clinical evidence arc — but Vafseo's Q3 revenues collapsed to $14.8M on TDAPA inventory destocking even as patients grew to 11,500, exposing the full brutality of the post-TDAPA price reset that starts January 1.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 29, 2026ReleaseAkebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
- Oct 26, 2026ReleaseU.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephro→ BD updateThe full VOICE dataset landed at ASN Kidney Week with new safety data — fewer serious adverse events and dramatically better hemoglobin control versus ESAs — giving Vafseo's sales force the peer-reviewed ammunition they need for post-TDAPA conversations, even as the structural risks I named in October remain unchanged.BD extracted 1 program update from this document → AKBA pipeline
- Oct 23, 20268-KCurrent report: listing notice
- Oct 14, 20268-KCurrent report: officer / director change→ BD updateAkebia's Chief Commercial Officer just resigned — effective November 6, 2026 — seven weeks before the TDAPA reimbursement cliff that management's own guidance says will cause Vafseo revenues to "decrease significantly" in 2027. The timing couldn't be worse, and the stock's 45.6% slide since the August update has already been pricing in bad news.
- Oct 7, 2026ReleaseAkebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
- Oct 6, 2026ReleaseAkebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
- Sep 14, 2026ReleaseAkebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesBD extracted 1 program update from this document → AKBA pipeline
- Sep 1, 2026ReleaseAkebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
- Aug 5, 2026ReleaseAkebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- Aug 5, 20268-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → AKBA pipeline
- Aug 5, 202610-QQuarterly report
- Aug 3, 2026ReleaseAkebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
- Jul 29, 2026ReleaseAkebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
- Jun 30, 2026ReleaseU.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
- Jun 30, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → AKBA pipeline
- Jun 22, 20268-KCurrent report: shareholder vote
- Jun 10, 2026ReleaseAkebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
- May 28, 2026ReleaseAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- May 7, 2026ReleaseAkebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Apr 1, 20268-KCurrent report: officer / director change · EX-99.1
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 5, 2026S-8Employee plan registration
- May 12, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 29, 2026ARSAnnual report to shareholders
- Apr 15, 2026PRE 14APRE 14A
- Mar 26, 2026SCHEDULE 13G/A13G amendment